InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,455.20
(
0.90%
)
Post# of 50894
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mick

Send PM Follow Ignore
Followers 3156
Posts 961240
Boards Moderated 205
Alias Born 09/04/2000

mick

Member Level

Re: mick post# 44700

Thursday, 05/23/2019 9:26:38 PM

Thursday, May 23, 2019 9:26:38 PM

Post# of 50894
Marker Therapeutics (NASDAQ: MRKR): Next Major Leap in T Cell-Based Immunotherapies for Cancer

Exclusive interview with Marker Therapeutics’ (NASDAQ: MRKR) Chief Development Officer Dr. Juan Vera. MRKR is in multiple active Phase 2 clinical trials in the $100+ billion market for immunotherapy cancer drugs. MRKR’s Multi-Antigen Targeted Cell Therapy Platform and Peptide Vaccine Portfolio has the potential to disrupt the CAR-T and TCR filed therapies.

https://www.redchip.com/corporate/media_production
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up